Aktuellt
SENASTE
Following the reported milestone of 2,000 patients treated with OssDsign Catalyst and the expanded FDA clearance, we lift our short-term and long-term earnings estimates. The milestone implies a significantly higher run rate in Q3 than we previously assumed, and the expanded FDA clearance should open new doors and increase the adoption rate. We reiterate our DCF-based mid-point equity valuation of SEK 12 per share.
LÄS MER
